Загрузка...
Galectin-3: an immune checkpoint target for musculoskeletal tumor patients
In the past decade, the development of immune checkpoint inhibitors in oncological clinical settings was in the forefront. However, the interest in musculoskeletal tumor patients as candidates for checkpoint inhibition remains underserved. Here, we are forwarding evidence proposing that galectin-3 (...
Сохранить в:
| Опубликовано в: : | Cancer Metastasis Rev |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer US
2020
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7897198/ https://ncbi.nlm.nih.gov/pubmed/32929561 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10555-020-09932-4 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|